

IF W

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 12, 2004

Signature:

Kurt T. Buechle
(Kurt T. Buechle)

Docket No.: 28967/39140B
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/772,927

Confirmation No.: 7264

Filed: February 4, 2004

Art Unit: 1653

For: VEGF-B AND PDGF MODULATION OF
STEM CELLS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

References from section B and C on the PTO/SB/08 are attached.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure statement shall not be construed


to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 28967/39140B. A copy of this paper is enclosed.

Dated: July 12, 2004

Respectfully submitted,

By 

Kurt T. Buechle

Registration No.: 54,011
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 12, 2004

Signature: 

(Kurt T. Buechle)

Docket No.: 28967/39140B
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/772,927

Confirmation No.: 7264

Filed: February 4, 2004

Art Unit: 1653

For: VEGF-B AND PDGF MODULATION OF
STEM CELLS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

References from section B and C on the PTO/SB/08 are attached.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure statement shall not be construed


to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 28967/39140B. A copy of this paper is enclosed.


Dated: July 12, 2004

Respectfully submitted,

By 

Kurt T. Buechle

Registration No.: 54,011
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 28967/39140B	Serial No. 10/772,927
 <p>INFORMATION DISCLOSURE STATEMENT</p>		Applicant Alitalo et al.	
		Filing Date February 4, 2004	Group 1653

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	4,845,075	07-04-1989	Murray et al.	514	12	
	A2	4,849,407	07-18-1989	Murray et al.	514	12	
	A3	4,889,919	12-26-1989	Murray et al.	530	351	
	A4	5,128,321	07-07-1992	Murray et al.	514	12	
	A5	5,149,792	09-22-1992	Thomason	530	399	
	A6	5,219,759	06-15-1993	Heldin et al.	435	320.1	
	A7	5,272,064	12-21-1993	Thomason	435	69.1	
	A8	5,428,010	06-27-1995	Murray et al.	514	12	
	A9	5,474,982	12-12-1995	Murray et al.	514	12	
	A10	5,498,600	03-12-1996	Murray et al.	514	12	
	A11	5,512,545	04-30-1996	Brown et al.	514	12	
	A12	5,516,896	05-14-1996	Murray et al.	530	399	
	A13	5,605,816	02-25-1997	Heldin et al.	435	69.4	
	A14	5,607,918	03-04-1997	Eriksson et al.	514	12	
	A15	5,759,815	06-02-1998	Charette et al.	435	69.4	
	A16	5,776,755	07-07-1998	Alitalo et al.	435	194	
	A17	5,840,693	11-24-1998	Eriksson et al.	514	12	
	A18	5,889,149	03-30-1999	Hart	530	350	
	A19	5,895,755	04-20-1999	Murray	435	69.4	
	A20	5,905,142	05-18-1999	Murray	530	399	
	A21	5,928,939	07-27-1999	Eriksson et al.	435	325	
	A22	5,932,540	08-03-1999	Hu et al.	514	2	
	A23	5,935,820	08-10-1999	Hu et al.	435	69.4	
	A24	5,952,199	09-14-1999	Davis-Smyth	435	69.7	
	A25	5,968,778	10-19-1999	Hoppe et al.	435	69.4	
	A26	6,001,802	12-14-1999	Jehanli et al.	514	11	
	A27	6,004,929	12-21-1999	Murray et al.	514	12	
	A28	6,040,157	03-21-2000	Hu et al.	435	69.4	
	A29	6,100,071	08-08-2000	Davis-Smyth	435	69.7	
	A30	6,107,046	08-22-2000	Alitalo et al.	435	7.1	
	A31	6,130,071	10-10-2000	Alitalo et al.	435	69.4	
	A32	6,221,839	04-24-2001	Alitalo et al.	512	12	
	A33	6,235,713	05-22-2001	Achen et al.	514	12	
	A34	6,245,530	06-12-2001	Alitalo et al.	435	6934	
	A35	6,262,337	07-17-2001	von Euler et al.	800	18	
	A36	6,331,302	12-18-2001	Bennett	424	146.1	
	A37	6,361,946	03-26-2002	Alitalo et al.	435	6	
	A38	6,383,484	05-07-2002	Achen et al.	424	133.1	
	A39	6,383,486	05-07-2002	Davis-Smyth	424	158.1	
	A40	6,403,088	06-11-2002	Alitalo	424	139.1	
	A41	6,451,764	09-17-2002	Lee et al.	514	12	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 28967/39140B	Serial No. 10/772,927
INFORMATION DISCLOSURE STATEMENT		Applicant Alitalo et al.	
		Filing Date February 4, 2004	Group 1653

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date If Appropriate
	A42	6,576,608	06-10-2003	Lee et al.	514	2	
	A43	6,608,182	08-19-2003	Rosen et al.	530	399	
	A44	6,645,933	11-11-2003	Alitalo et al.	514	2	
	A45	6,673,343	01-06-2004	Bennett et al.	424	133.1	
	A46	6,689,580	02-10-2004	Achen et al.	435	69.1	
	A47	6,730,658	05-04-2004	Alitalo et al.	514	12	
	A48	2001/0038842	11-08-2001	Achen et al.			03-02-2001
	A49	2002/0049987	04-25-2002	Eriksson et al.			03-28-2001
	A50	2002/0065218	05-30-2002	Achen et al.			01-18-2001
	A51	2002/0068694	06-06-2002	Jeltsch et al.	514	8	07-26-2001
	A52	2002/0102260	08-01-2002	Achen et al.			09-20-2001
	A53	2002/0120123	08-29-2002	Rosen et al.			04-23-2002
	A54	2002/0123481	09-05-2002	Oliviero, S.			05-07-2002
	A55	2002/0127222	09-12-2002	Achen et al.			12-23-1998
	A56	2002/0146420	10-10-2002	Bennett et al.			10-17-2001
	A57	2002/0151489	10-17-2002	Gavereaux et al.			10-02-2001
	A58	2002/0164687	11-07-2002	Eriksson et al.			
	A59	2002/0164710	11-07-2002	Eriksson et al.			03-04-2002
	A60	2002/0182683	12-05-2002	Hu et al.			02-01-2002
	A62	2002/0197691	12-26-2002	Sugiyama, J.			04-29-2002
	A62	2003/0008357	01-09-2003	Hu et al.			08-24-2001
	A63	2003/0008824	01-09-2003	Eriksson et al.			06-20-2002
	A64	2003/0028007	02-06-2003	Hu et al.			02-28-2002
	A65	2003/0091567	05-15-2003	Alitalo et al.			07-23-2002
	A66	2003/0092604	05-15-2003	Alitalo et al.			07-23-2002
	A67	2003/0125537	07-03-2003	Achen et al.			06-05-2002
	A68	2003/0166523	09-04-2003	Achen et al.			05-03-2001
	A69	2003/0166547	09-04-2003	Oliviero, S.			06-19-2002
	A70	2003/0166873	09-04-2003	Lee et al.			01-17-2003
	A71	2003/0170786	09-11-2003	Rosen et al.			04-12-2002
	A72	2003/0175274	09-18-2003	Rosen et al.			04-12-2002
	A73	2003/0176674	09-18-2003	Rosen et al.			04-12-2002
	A74	2003/0180294	09-25-2003	DeVries, G.			02-22-2002
	A75	2003/0211101	11-13-2003	Wise et al.			01-28-2003
	A76	2003/0211988	11-13-2003	Epstein, S.			02-14-2003
	A77	2003/0211994	11-13-2003	Li et al.			11-26-2002
	A78	2003/0215921	11-20-2003	Coleman, T.			08-03-2001
	A79	2003/0228283	12-11-2003	Heinzerling et al.			04-29-2003
	A80	2003/0232437	12-18-2003	Zhang et al.			06-17-2002
	A81	2004/0037820	02-26-2004	Alitalo et al.			01-19-2001

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 28967/39140B	Serial No. 10/772,927
INFORMATION DISCLOSURE STATEMENT		Applicant Alitalo et al.	
		Filing Date February 4, 2004	Group 1653

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	EP 0935001	08-11-1999	EPO				
	B2	WO 96/26736	09-06-1996	PCT				
	B3	WO 96/39421	12-12-1996	PCT				
	B4	WO 97/12972	04-10-1997	PCT				
	B5	WO 98/02543	01-22-1998	PCT				
	B6	WO 00/18212	04-06-2000	PCT				
	B7	WO 00/27879	05-18-2000	PCT				
	B8	WO 00/45835	08-10-2000	PCT				
	B9	WO 02/07514	01-31-2002	PCT				
	B10	WO 02/36131	05-10-2002	PCT				
	B11	WO 02/070008	09-12-2002	PCT				
	B12	WO 03/014326	02-20-2003	PCT				
	B13	WO 03/074005	09-12-2003	PCT				
	B14	WO 2004/009773	01-29-2004	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C1	Eriksson et al., "VEGF Receptor 1 Stimulates Stem-Cell Recruitment and New Hope for Angiogenesis Therapies," Nature Medicine, 8(8):775-777, (2002).
	C2	Carmeliet et al., "Synergism Between Vascular Endothelial Growth Factor and Placental Growth Factor Contributes to Angiogenesis and Plasma Extravasation in Pathological Conditions," Nature Medicine, 7(5):575-583, (2001).
	C3	Pietras et al., "PDGF Receptors as Cancer Drug Targets," Cancer Cell, 3:439-443, (May 2003).
	C4	Tepper, et al., "Endothelial Progenitor Cells: The Promise of Vascular Stem Cells for Plastic Surgery," Plastic and Reconstructive Surgery, 111(2): 846-854, (February 2003).
	C5	Hattori, et al., "Placental Growth Factor Reconstitutes Hematopoiesis by Recruiting VEGFR1 ⁺ Stem Cells from Bone-Marrow Microenvironment," Nature Medicine, 8(8):841-849, (August 2002).
	C6	Luttun et al., "Revascularization of Ischemic Tissues by PIFG Treatment, and Inhibition of Tumor Angiogenesis, Arthritis and Atherosclerosis by Anti-Flt1," Nature Medicine, 8(8):831-840, (August 2002).
	C7	Olofsson et al., "Vascular Endothelial Growth Factor B (VEGF-B) Binds to VEGF Receptor-1 and Regulates Plasminogen Activator Activity in Endothelial Cells," Proc. Natl. Acad. Sci. USA 95:11709-11714, (September 1998).
	C8	Wanstall, et al., "Vascular Endothelial Growth Factor-B-Deficient Mice Show Impaired Development of Hypoxic Pulmonary Hypertension," Cardiovascular Research 55:361-368, (2002).
	C9	Fan et al., "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in the Management of Cancer," in vivo 5:571-577, (1991).

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 28967/39140B	Serial No. 10/772,927
INFORMATION DISCLOSURE STATEMENT		Applicant Alitalo et al.	
		Filing Date February 4, 2004	Group 1653

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C10	Aase et al., "Vascular Endothelial Growth Factor-B-Deficient Mice Display an Atrial Conduction Defect," Circulation, (July 17, 2001).
	C11	Carmeliet et al., "Synergism Between Vascular Endothelial Growth Factor and Placental Growth Factor Contributes to Angiogenesis and Plasma Extravasation in Pathological Conditions," Nature Medicine 7(5):575-583, (May 2001).
	C12	Groopman, J., "Clinical Applications of Colony-Stimulating Factors," Seminars in Oncology, 15(6):27-33, (December 1988).
	C13	Peters, W., "The Effect of Recombinant Human Colony-Stimulating Factors on Hematopoietic Reconstitution Following Autologous Bone Marrow Transplantation," Seminars in Hematology, 26(2):18-23, (April 1989).
	C14	Smits et al., "Coexpression of Platelet-Derived Growth Factor α and β Receptors on Medulloblastomas and Other Primitive Neuroectodermal Tumors is Consistent with an Immature stem Cell and Neuronal Derivation," Laboratory Investigation, 74(1):188-198, (1996).
	C15	Ijichi et al., "Ex Vivo Gene Delivery of Platelet-Derived Growth Factor Increases O-2A Progenitors in Adult Rat Spinal Cord," Gene Therapy, 3:389-395, (1996).
	C16	Franklin et al., "Transplanting Oligodendrocyte Progenitors into the Adult CNS," J. Anat., 190:23-33, (1997).
	C17	Li et al., "Isoform-Specific Expression of VEGF-B in Normal Tissues and Tumors," Growth Factor, 19:49-59, (2001).
	C18	Gerber et al., "VEGF Regulates Haematopoietic Stem Cell Survival by an Internal Autocrine Loop Mechanism," Nature, 417:954-958, (June 27, 2002).
	C19	Kaushal et al., "Functional small-Diameter Neovessels Created Using Endothelial Progenitor Cells Expanded Ex Vivo," Nature Medicine, 7(9):1035-1040, (September 2001).
	C20	Tepper et al., "Endothelial Progenitor Cells: The Promise of Vascular Stem Cells for Plastic Surgery," Plastic and Reconstructive Surgery, 111(2):846-854, (February 2003).
	C21	Jiang et al., "Multipotent Progeintor Cells can be Isolated from Postnatal Murine Bown Marrow, Muscle, and Brain," Experimental Hematology, 30:896-904, (2002).
	C22	Su et al., "Platelet-Derived Growth Factor Promotes Ex Vivo Expansion of CD34 ⁺ Cells from Human Cord Blood and Enhances Long-Term Culture-Initiating Cells, Non-Obese Diabetic/Severe Combined Immunodeficient Repopulating Cells and Formation of Adherent Cells," British Journal of Haematology, 117:735-746, (2002).
	C23	Foss et al., "Peripheral Blood Progenitor Cell Grafts Contain High Levels of Platelet-Secreted Mediators," Transfusion, 41:1431-1437, (November 2001).
	C24	Su et al., "Platlet-Derived Growth Factor Enhances Ex Vivo Expansion of Megakaryocytic Progenitors from Human Cord Blood," Bone Marrow Transplantation 27:1075-1080, (2001).
	C25	Kaminski et al., "Basis of Hematopoietic Defects in Platelet-Derived Growth Factor (PDGF)-B and PDGF β -receptor Null Mice," Blood, 97(7):1990-1998, (April 1, 2001).
	C26	Hiragun et al., "A Fibrogenic Cytokine, Platelet-Derived Growth fActor (PDGF), Enhances Mast Cell Growth Indirectly via a SCF- and Fibroblast-Dependent Pathway," J. Invest Dermatol, 111:213-217, (1998).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT		28967/39140B	10/772,927
	Applicant	Alitalo et al.	
Filing Date	Group		
February 4, 2004	1653		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C27	Katz et al., "Effect of Platelet-Derived Growth factor on Enriched Populations of Haemopoietic Progenitors from Patients with Chronic Myeloid Leukaemia," Leukemia Research, 11(4):339-344, (1987).
	C28	Matthias Clauss, Ph.D., "Molecular Biology of the VEGF and the VEGF Receptor Family," Seminars In Thrombosis And Hemostasis, 26(5):561-569, (2000).

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	